The liver is the primary organ where biotransformation processes for drugs and other xenobiotics, necessary to turn originally fat-soluble compounds into more polar substances to facilitate urinary clearance, take place. Therefore, liver disease commonly brings about changes in the metabolism of multiple drugs. In addition to pharmacokinetic changes, chronic liver disease (particularly decompensated liver cirrhosis) induces changes (that is, an abnormal response) in the pharmacodynamics of various drugs and increases the severity of potential adverse events.
patients with cirrhosis, most particularly since it provides a rapid search and summarizes items to be considered for proper dosing as well as options to be avoided. However, many gaps remain inevitable as neither during drug development nor post-marketing studies are available that have examined the kinetics and response, as well as the potential toxicities of most drugs in this population. Although both the FDA and EMA demand since 2003 and 2005, respectively , that kinetic studies be performed before registration in patients with cirrhosis should the drug undergo significant hepatic metabolism, these studies are carried out in patients with preserved liver function (Child-Pugh A) and results can hardly be extrapolated to drugs with linear dynamics for dose titration purposes, since differences in liver metabolism are sometimes only apparent in Child-Pugh C patients (4) .
In association with the update suggested by studies such as the one by Periáñez et al. (3) , knowing the attitudes of clinicians when prescribing drugs for patients with liver disease would be useful to identify behaviors susceptible of intervention should deviation from scientific evidence occur. However, very few such surveys have been reported. A survey in four US healthcare areas among internists, general practitioners and specialists revealed a lower trend towards discouraging the use of NSAIDs versus paracetamol in patients with both compensated and decompensated cirrhosis; however, while non-specialists were less apt to recommend paracetamol versus NSAIDs for these patients, specialists had the opposite behavior. Anyway, the caution usually displayed by respondents suggests that pain management in cirrhosis might be insufficiently approached (5) . On the other hand, a survey carried out in Spain a few years ago to review the way gastroenterology/hepatology specialists use drugs in inpatients with liver cirrhosis similarly showed a conservative attitude with a tendency to prescribe an average < 1 of the daily dose defined for drugs most commonly indicated for conditions associated with liver disease (including paracetamol, glibenclamide, lorazepam, captopril, and tiapride), with clomethiazole and amoxicillin-clavulanic -the use of which is controversial in the setting of cirrhosis-at the top of the list (6). However, the most relevant finding by this extensive survey was a high variability in prescription patterns for drugs indicated in liver conditions, with a relevant use of drugs such as vitamin K and proton-pump inhibitors (PPIs) (7). This finding was hardly surprising regarding PPIs, given the widespread tendency of physicians to prescribe them as "protectors" particularly in frail subjects such as elderly, polymedicated individuals, or patients with chronic conditions such as cirrhosis. In the latter case a study to assess PPI indication in this population found that 51/128 patients (40%) received antisecretory drugs, the indication (history of portal hypertension-related bleeding) being unwarranted in 63% (8) . In fact, in the context of cirrhosis PPIs are indicated primarily for patients with esophageal varices or gastric disease related to portal hypertension, particularly those undergoing endoscopic therapy. Nevertheless, a number of studies have shown these agents to be ineffective both in the prevention and management of portal hypertension-related bleeding (9, 10) , and in the prevention and management of ulcers following sclerotherapy or band ligation (11) . While this antisecretory prescribing behavior for cirrhotic patients merely was a non-evidence-based -and therefore non-cost-effective-deviation (12) , recent studies clearly show that PPI use is not without risks. These drugs increase fracture risk in frail subjects (13) , and various studies suggest that PPIinduced antisecretion favors bacterial overgrowth and bacterial translocation in the setting of increased bowel permeability as seen in portal hypertension (14) , thus increasing the risk for spontaneous bacterial peritonitis (15) . While the studies that revealed an association with bacterial peritonitis are retrospective and some of them had small cohorts and inconsistent results, a recent meta-analysis including almost 800 patients confirmed such association and showed that PPIs induce a 3-fold increase in this cirrhotic complication (OR = 2.77; 95% CI: 1.82-4.23) (16) . The risk for infection in cirrhotic patients exposed to PPIs is not restricted to spontaneous bacterial peritonitis but is also linked to Clostridium difficile infection (17) , a condition with a high death rate in patients with liver cirrhosis. In fact, prior PPI use was the weightiest risk factor in the multivariate analysis -OR = 37.6 (95% CI: 6.22-227.6), p < 0.0005-, even above inpatient antibiotic use -OR = 11.6 (95% CI: 2.63-51.05), p < 0.001-. While this association is no evidence for causality -particularly given that Clostridium difficile spores are acid-resistant, and the potential impact of avoiding antisecretory drugs on this infection remains unknown (18) , it does represent, together with the above evidence, a warning to physicians, particularly those involved in caring for patients with liver disease, regarding the fact that efforts should be devoted to reviewing every patient on these drugs in order to withdraw such medication if no indication is warranted. Further studies are thus needed to assess the prescription-related beliefs and attitudes of gastroenterologists regarding these medications in cirrhotic patients. This group represents the primary target for any field studies and resulting interventions, not only because they hold the maximum responsibility in decision-making regarding the medication of patients with chronic liver disease, but also because of the multiplying effect any educational program targeting them will have on other groups such as the internists and general practitioners involved in the management of these patients.
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